CAR T cells offer hope in glioblastoma
Novel chimeric antigen receptor (CAR) T cells delivered directly to the CNS could have therapeutic effects in recurrent glioblastoma, according to two early-stage trials. If the effects are sustained and reproducible, the approach has potential to increase survival in the most lethal form of brain cancer.